Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma

[1]  R. Andersson,et al.  Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma , 2018, BMC Cancer.

[2]  M. Weniger,et al.  The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship , 2018, Cancers.

[3]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[4]  A. Scope,et al.  NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis , 2018, Immunity.

[5]  H. Friess,et al.  Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment , 2018, Oncotarget.

[6]  G. Marko‐Varga,et al.  Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma , 2018, Oncotarget.

[7]  S. Richon,et al.  Cancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assembly , 2017, The Journal of cell biology.

[8]  G. Long,et al.  Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice , 2017, Current opinion in oncology.

[9]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[10]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[11]  R. Brekken,et al.  Matrix control of pancreatic cancer: New insights into fibronectin signaling. , 2016, Cancer letters.

[12]  R. Andersson,et al.  The role of SPARC expression in pancreatic cancer progression and patient survival , 2015, Scandinavian journal of gastroenterology.

[13]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[14]  J. Berlin,et al.  A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[15]  D. Figarella-Branger,et al.  Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice , 2014, Oncogene.

[16]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[17]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[18]  R. Muschel,et al.  The stromal compartments in pancreatic cancer: are there any therapeutic targets? , 2014, Cancer letters.

[19]  S. Yamada,et al.  Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. , 2013, Surgery.

[20]  S. Bender,et al.  Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. , 2010, Cancer research.

[21]  Wei Liu,et al.  The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. , 2008, Cancer research.

[22]  M. Basik,et al.  Tissue microarrays: emerging standard for biomarker validation. , 2008, Current opinion in biotechnology.

[23]  R. Dubridge,et al.  Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits , 2008, Investigational new drugs.

[24]  R. Dubridge,et al.  A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo , 2007, Journal of Translational Medicine.

[25]  T. Khoury,et al.  Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer , 2007, Annals of Surgical Oncology.

[26]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[27]  R. Hruban,et al.  Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways , 2005, Modern Pathology.

[28]  K. Tsuchida,et al.  Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.

[29]  R. Hruban,et al.  SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.

[30]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[31]  Kenneth M. Yamada,et al.  Fibronectin at a glance , 2002, Journal of Cell Science.

[32]  S. Gansauge,et al.  Altered expression of extracellular matrix molecules and their receptors in chronic pancreatitis and pancreatic adenocarcinoma in comparison with normal pancreas , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[33]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.